blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2455404

EP2455404 - Anti-C5AR antibodies with improved properties [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.12.2016
Database last updated on 11.04.2026
Most recent event   Tooltip20.07.2018Lapse of the patent in a contracting state
New state(s): MT		published on 22.08.2018  [2018/34]
Applicant(s)For all designated states
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd / DK
[2016/06]
Former [2015/34]For all designated states
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd / DK
Former [2012/21]For all designated states
G2 Inflammation Pty Ltd
Level 10, 384 Victoria Street
Darlinghurst, NSW 2010 / AU
Inventor(s)01 / Mackay, Charles Reay
12 Grandview Grove
Prahran Victoria 3181 / AU
 [2016/06]
Former [2012/40]01 / Mackay, Charles Reay
12 Grandview Grove
Prahtan Victoria 3181 / AU
Former [2012/38]01 / Mackay, Charles Reay
1 Belah Gardens Vaucluse
New South Wales 2030 / AU
Former [2012/21]01 / Mackay, Charles
Reay of 1 Belah Gardens Vaucluse
New South Wales 2030 / AU
Representative(s)Petersen, Birgit Otzen
Novo Nordisk A/S
Corporate Patents
Novo Allé
2880 Bagsværd / DK
[2016/06]
Former [2012/21]O'Neill, Michelle
Harrison IP
1st Floor, Box Tree House
Northminster Business Park
Northfield Lane
York, YO26 6QU / GB
Application number, filing date12155157.622.08.2007
[2012/21]
Priority number, dateUS20060839634P22.08.2006         Original published format: US 839634 P
[2012/21]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2455404
Date:23.05.2012
Language:EN
[2012/21]
Type: A3 Search report 
No.:EP2455404
Date:02.01.2013
Language:EN
[2013/01]
Type: B1 Patent specification 
No.:EP2455404
Date:10.02.2016
Language:EN
[2016/06]
Search report(s)(Supplementary) European search report - dispatched on:EP05.12.2012
ClassificationIPC:C07K16/28, A61P37/02, A61K39/395, C12N5/20, C12N5/12
[2012/21]
CPC:
C07K16/2896 (EP,US); C07K16/28 (KR); A61K39/395 (KR);
A61P1/04 (EP); A61P11/00 (EP); A61P11/02 (EP);
A61P11/06 (EP); A61P11/16 (EP); A61P13/12 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P17/04 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P21/04 (EP);
A61P25/00 (EP); A61P25/28 (EP); A61P27/02 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/04 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P37/08 (EP);
A61P9/10 (EP); A61P9/14 (EP); C12N5/16 (KR);
C07K2317/34 (EP,US); C07K2317/56 (EP,US); C07K2317/565 (EP,US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/06]
Former [2012/21]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Anti-C5AR-Antikörper mit verbesserten Eigenschaften[2012/21]
English:Anti-C5AR antibodies with improved properties[2012/21]
French:Anticorps anti-C5AR possédant des propriétés améliorées[2012/21]
Biological materialThis application mentions deposited biological material, check the file for details
Examination procedure27.06.2013Amendment by applicant (claims and/or description)
27.06.2013Examination requested  [2013/32]
28.05.2014Despatch of a communication from the examining division (Time limit: M04)
08.09.2014Reply to a communication from the examining division
06.08.2015Communication of intention to grant the patent
03.11.2015Fee for grant paid
03.11.2015Fee for publishing/printing paid
04.12.2015Information about intention to grant a patent
04.12.2015Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07784844.8  / EP2051997
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20070784844) is  16.02.2010
Opposition(s)11.11.2016No opposition filed within time limit [2017/03]
Fees paidRenewal fee
13.02.2012Renewal fee patent year 03
13.02.2012Renewal fee patent year 04
13.02.2012Renewal fee patent year 05
10.08.2012Renewal fee patent year 06
19.08.2013Renewal fee patent year 07
13.08.2014Renewal fee patent year 08
10.08.2015Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.08.2007
AT10.02.2016
BE10.02.2016
CY10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SI10.02.2016
SK10.02.2016
TR10.02.2016
BG10.05.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
IE22.08.2016
LU22.08.2016
CH31.08.2016
LI31.08.2016
MT31.08.2016
[2018/33]
Former [2018/29]HU22.08.2007
AT10.02.2016
BE10.02.2016
CY10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SI10.02.2016
SK10.02.2016
TR10.02.2016
BG10.05.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
IE22.08.2016
LU22.08.2016
CH31.08.2016
LI31.08.2016
Former [2018/28]HU22.08.2007
AT10.02.2016
BE10.02.2016
CY10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SI10.02.2016
SK10.02.2016
BG10.05.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
IE22.08.2016
LU22.08.2016
CH31.08.2016
LI31.08.2016
Former [2017/41]AT10.02.2016
BE10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SI10.02.2016
SK10.02.2016
BG10.05.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
IE22.08.2016
LU22.08.2016
CH31.08.2016
LI31.08.2016
Former [2017/19]AT10.02.2016
BE10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SI10.02.2016
SK10.02.2016
BG10.05.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
CH31.08.2016
LI31.08.2016
Former [2017/15]AT10.02.2016
BE10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
MC10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SI10.02.2016
SK10.02.2016
BG10.05.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2017/03]AT10.02.2016
BE10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SK10.02.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/50]AT10.02.2016
CZ10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
NL10.02.2016
PL10.02.2016
RO10.02.2016
SE10.02.2016
SK10.02.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/49]AT10.02.2016
DK10.02.2016
EE10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
NL10.02.2016
PL10.02.2016
SE10.02.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/46]AT10.02.2016
DK10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
NL10.02.2016
PL10.02.2016
SE10.02.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/39]AT10.02.2016
FI10.02.2016
LT10.02.2016
LV10.02.2016
NL10.02.2016
PL10.02.2016
SE10.02.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/38]AT10.02.2016
FI10.02.2016
LT10.02.2016
NL10.02.2016
PL10.02.2016
GR11.05.2016
IS10.06.2016
PT13.06.2016
Former [2016/36]AT10.02.2016
FI10.02.2016
LT10.02.2016
NL10.02.2016
PL10.02.2016
GR11.05.2016
Former [2016/35]FI10.02.2016
GR11.05.2016
Documents cited:Search[ID] WO03062278  (G2 THERAPIES LTD et al.)
 [A]   PROCTOR L M ET AL: "Recent developments in C5/C5a inhibitors", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 16, no. 4, 1 April 2006 (2006-04-01), pages 445 - 458, XP002509476, ISSN: 1354-3776

DOI:   http://dx.doi.org/10.1517/13543776.16.4.445
 [A]   OPPERMANN M ET AL: "Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. identification of a potential ligand binding site on the NH2-terminal domain", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 151, no. 7, 1 October 1993 (1993-10-01), pages 3785 - 3794, XP002992811, ISSN: 0022-1767
 [AD]   WATANABE H ET AL: "Analysis of C5a receptor by monoclonal antibody", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 185, no. 1, 11 September 1995 (1995-09-11), pages 19 - 29, XP004021151, ISSN: 0022-1759

DOI:   http://dx.doi.org/10.1016/0022-1759(95)00101-F
 [AD]   MORGAN E L ET AL: "ANTI-C5A RECEPTOR ANTIBODIES CHARACTERIZATION OF NEUTRALIZING ANTIBODIES SPECIFIC FOR A PEPTIDE, C5AR-(9-29), DERIVED FROM THE PREDICTED AMINO-TERMINAL SEQUENCE OF THE HUMAN C5A RECEPTOR", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 151, no. 1, 1 July 1993 (1993-07-01), pages 377 - 388, XP008052222, ISSN: 0022-1767
 [A]   LILI HUANG ET AL: "Discovery of human antibodies against the C5aR target using phage display technology", JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 18, no. 4, 1 June 2005 (2005-06-01), pages 327 - 333, XP002656207, ISSN: 0952-3499, [retrieved on 20050210], DOI: 10.1002/JMR.735

DOI:   http://dx.doi.org/10.1002/JMR.735
 [A]   ROBINSON ET AL: "Improving monoclonal antibodies for cancer therapy", DRUG DEVELOPMENT RESEARCH, vol. 61, no. 3, March 2004 (2004-03-01), pages 172 - 187, XP002548024

DOI:   http://dx.doi.org/10.1002/DDR.10345
 [A]   JEFFERY M KLCO ET AL: "Essential role for the second extracellular loop in C5a receptor activation", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 12, no. 4, 1 April 2005 (2005-04-01), pages 320 - 326, XP055044491, ISSN: 1545-9993, DOI: 10.1038/nsmb913

DOI:   http://dx.doi.org/10.1038/nsmb913
 [A]   SUMICHIKA H: "C5A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 5, no. 5, 1 May 2004 (2004-05-01), pages 505 - 510, XP009061611, ISSN: 1472-4472
 [A]   RAFFETSEDER U ET AL: "SITE-DIRECTED MUTAGENESIS OF CONSERVED CHARGED RESIDUES IN THE HELICAL REGION OF THE HUMAN C5A RECEPTOR ARG206 DETERMINES HIGH-AFFINITY BINDING SITES OF C5A RECEPTOR", EUROPEAN JOURNAL OF BIOCHEMISTRY, BLACKWELL PUBLISHING, BERLIN, DE, vol. 235, no. 1/02, 1 January 1996 (1996-01-01), pages 82 - 92, XP008029369, ISSN: 0014-2956, DOI: 10.1111/J.1432-1033.1996.00082.X

DOI:   http://dx.doi.org/10.1111/j.1432-1033.1996.00082.x
 [T]   ANONYMOUS: "Alignment of human and mouse C5aR sequences", 19 November 2012 (2012-11-19), pages 1 - 2, XP002687529, Retrieved from the Internet [retrieved on 20121119]
Examination  ANONYMOUS: "Notice from the European Patent Office dated 7 July 2010 concerning inventions which involve the use of or concern biological material", 498 AMTSBLATT EPA OFFICIAL JOURNAL EPO JOURNAL OFFICIEL OEB, 1 January 2010 (2010-01-01), pages 498 - 513, XP055107476, Retrieved from the Internet [retrieved on 20140313]
   ANONYMOUS: "PART I: GENERAL REQUIREMENTS FOR DEPOSIT AND FURNISHING OF SAMPLES", WIPO, 4 April 2006 (2006-04-04), pages 1 - 28, XP055107484, Retrieved from the Internet [retrieved on 20140313]
by applicantWO9500164
 WO03062278
 US4816567
 US5545807
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
 WO9308829
 WO9627011
 US4676980
 WO9100360
 WO9220373
 EP0003089
 WO9411026
 US5284746
 WO9420142
 US3817827
 US3850752
 US3901654
 US4098876
 US5354678
   DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387
   ATSCHUL ET AL., J. MOL. BIOL., 1990, pages 403 - 410
   KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495
   GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
   KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
   BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
   MUNSON; POLLARD, ANAL. BIOCHEM., vol. 107, 1980, pages 220
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
   PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
   VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
   HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381
   MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581
   COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, pages: 77
   BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95
   MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
   LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859
   MORRISON, NATURE, vol. 368, 1994, pages 812 - 813
   FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 851
   NEUBERGER, NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826
   LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
   MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537 - 539
   TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659
   SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210
   BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
   SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 - 225
   KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
   HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
   GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368
   TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60
   CARON ET AL., J. EXP MED., vol. 176, 1992, pages 1191 - 1195
   SHOPES, J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922
   WOLFF ET AL., CANCER RESEARCH, vol. 53, 1993, pages 2560 - 2565
   STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, vol. 3, 1989, pages 219 - 230
   VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098
   STEPLEWSKI ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 8653
   SPIRA ET AL., J. IMMUNOL. METHODS, vol. 74, 1984, pages 307
   NEOTE, K. ET AL., CELL, vol. 72, 1993, pages 415 - 425
   VAN RIPER ET AL., J. EXP. MED., vol. 177, 1993, pages 851 - 856
   DAHINDEN, C. A. ET AL., J. EXP. MED., vol. 179, 1994, pages 751 - 756
   BERMAN ET AL., IMMUNOL. INVEST., vol. 17, 1988, pages 625 - 677
   KAVANAUGH ET AL., J. IMMUNOL., vol. 146, 1991, pages 4149 - 4156
   VAN DAMME, J. ET AL., J. EXP. MED., vol. 176, 1992, pages 59 - 65
   ZACHARIAE, C. O. C. ET AL., J. EXP. MED., vol. 171, 1990, pages 2177 - 2182
   JOSE, P. J. ET AL., J. EXP. MED., vol. 179, 1994, pages 881 - 887
   "Remington's Pharmaceutical Science", 1980, MACK
   SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRINGS HARBOUR LABORATORY PRESS
   ALLEGRETTI, M. ET AL.: "Targeting C5a: recent advances in drug discovery.", CURR. MED. CHEM., vol. 12, 2005, pages 217 - 236, XP009044681
   CAMPBELL, J.J.; QIN, S; BACON, K.B.; MACKAY, C.R.; BUTCHER, E.C.: "Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells.", J CELL BIOL, vol. 134, 1996, pages 255 - 266
   GERARD, C.; GERARD, N.P.: "C5A anaphylatoxin and its seven transmembrane-segment receptor.", ANNU. REV. IMMUNOL., vol. 12, 1994, pages 775 - 808, XP000579211, DOI: doi:10.1146/annurev.iy.12.040194.004015

DOI:   http://dx.doi.org/10.1146/annurev.iy.12.040194.004015
   GRANT, E.P. ET AL.: "Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis.", J. EXP. MED, vol. 196, 2002, pages 1461 - 1471
   GUO, R.F.; WARD, P.A.: "Role of C5a in inflammatory responses.", ANNU. REV. IMMUNOL., vol. 23, 2005, pages 821 - 852
   HASLETT, C.; GUTHRIE, L.A.; KOPANIAK, M.M.; JOHNSTON, R.B., JR; HENSON, P.M.: "Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide", AM JPATHOL, vol. 119, 1985, pages 101 - 110
   HEATH, H. ET AL.: "Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.", 1 CLIN. INVEST., vol. 99, 1997, pages 178 - 184
   JI, H. ET AL.: "Arthritis critically dependent on innate immune system players.", IMMUNITY, vol. 16, 2002, pages 157 - 168, XP002968950, DOI: doi:10.1016/S1074-7613(02)00275-3

DOI:   http://dx.doi.org/10.1016/S1074-7613(02)00275-3
   KANEKO, Y. ET AL.: "Antagonistic peptides against human anaphylatoxin C5a", IMMUNOLOGY, vol. 86, no. 1, 1995, pages 149 - 154, XP000523705
   KLCO, J.M. ET AL., NAT STRUCT MOL BIOL., vol. 12, 2005, pages 320 - 326
   KONTEATIS, Z.D. ET AL.: "Development of C5a receptor antagonists. Differential loss of functional responses.", JOURNAL OF IMMUNOLOGY, vol. 153, no. 9, 1994, pages 4200 - 4205
   KORGANOW, A.S. ET AL.: "From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins.", IMMUNITY, vol. 10, 1999, pages 451 - 461, XP000944280, DOI: doi:10.1016/S1074-7613(00)80045-X

DOI:   http://dx.doi.org/10.1016/S1074-7613(00)80045-X
   KOUSKOFF, V. ET AL.: "Organ-specific disease provoked by systemic autoimmunity.", CELL, vol. 87, 1996, pages 811 - 822, XP002155989, DOI: doi:10.1016/S0092-8674(00)81989-3

DOI:   http://dx.doi.org/10.1016/S0092-8674(00)81989-3
   LUSTER, A.D.; ALON, R; VON ANDRIAN, U.H.: "Immune cell migration in inflammation: present and future therapeutic targets", NAT. IMMUNOL., vol. 6, 2005, pages 1182 - 1190, XP003014218, DOI: doi:10.1038/ni1275

DOI:   http://dx.doi.org/10.1038/ni1275
   MACKAY, C.R.: "Chemokines: immunology's high impact factors.", NAT. IMMUNOL., vol. 2, 2001, pages 95 - 101
   MORGAN, E.L. ET AL.: "Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted aminoterminal sequence of the human C5a receptor.", JOURNAL OF IMMUNOLOGY, vol. 151, no. 1, 1993, pages 377 - 388, XP008052222
   MURDOCH, C.; A. FINN: "Chemokine receptors and their role in inflammation and infectious diseases.", BLOOD, vol. 95, no. 10, 2000, pages 3032 - 3043, XP002238189
   MURPHY, P.M.: "The molecular biology of leukocyte chemoattractant receptors", ANNU. REV. IMMUNOL., vol. 12, 1994, pages 593 - 633, XP002912601, DOI: doi:10.1146/annurev.iy.12.040194.003113

DOI:   http://dx.doi.org/10.1146/annurev.iy.12.040194.003113
   PELLAS, T.C. ET AL.: "Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo", JOURNAL OF IMMUNOLOGY, vol. 160, no. 11, 1998, pages 5616 - 5621, XP002210872
   PONATH, P.D. ET AL.: "Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils.", J. CLIN. INVEST., vol. 97, 1996, pages 604 - 612
   QIN, S. ET AL.: "Expression of monocyte chemoattractant protein- and interleukin-8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential.", EUR. I IMMUNOL., vol. 26, 1996, pages 640 - 647, XP008035052, DOI: doi:10.1002/eji.1830260320

DOI:   http://dx.doi.org/10.1002/eji.1830260320
   QIN, S. ET AL.: "The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.", J. CLIN. INVEST., vol. 101, 1998, pages 746 - 754, XP002925205, DOI: doi:10.1172/JCI1422

DOI:   http://dx.doi.org/10.1172/JCI1422
   RIEDEMANN, N.C.; GUO, R.F.; WARD, P.A.: "The enigma of sepsis.", J CLIN. INVEST., vol. 112, 2003, pages 460 - 467
   SHEVCHUK, N.A.: "Construction of long DNA molecules using long PCR-based fusion of several fragments simultaneously.", NUCLEIC ACIDS RES, vol. 32, 2004, pages EL9
   SUMICHIKA, H.: "C5a receptor antagonists for the treatment of inflammation.", CURR OPIN INVESTIG DRUGS, vol. 5, 2004, pages 505 - 510, XP009061611
   VON ANDRIAN, U.H.; MACKAY, C.R.: "T-cell function and migration. Two sides of the same coin.", N. ENGL. J. MED., vol. 343, 2000, pages 1020 - 1034, XP001029001, DOI: doi:10.1056/NEJM200010053431407

DOI:   http://dx.doi.org/10.1056/NEJM200010053431407
   WANG, Y.; ROLLINS, S.A.; MADRI, J.A.; MATIS, L.A.: "Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease", PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 8955 - 8959, XP055000476

DOI:   http://dx.doi.org/10.1073/pnas.92.19.8955
   WATANABE, H. ET AL.: "Analysis of C5a receptor by monoclonal antibody.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 185, no. 1, 1995, pages 19 - 29
   WU, L. ET AL.: "Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.", J EXP. MED., vol. 186, 1997, pages 1373 - 1381, XP002944588, DOI: doi:10.1084/jem.186.8.1373

DOI:   http://dx.doi.org/10.1084/jem.186.8.1373
   WURCH, T.; COLPAERT, F.C.; PAUWELS, P.J.: "Chimeric receptor analysis of the ketanserin binding site in the human 5-Hydroxytryptamine 1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding.", MOL PHARMACOL, vol. 54, 1998, pages 1088 - 1096
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.